Novel peptide-based therapeutic
|AFFILIATION:||University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|
Track: Medical & Biotech
Area: Infectious Disease
Tech Readiness: TRL 3
Tech Brief: Our technology enhances our body's immune defense mechanisms in a very unique fashion for the treatment of difficult-to-treat infections in critically ill patients.
Value Proposition: Since the SPA4 peptide targets host-immune system via TLR4 and does not even interact with pathogen, we believe that the SPA4 peptide will provide a much more effective solution in the clinics and intensive care units to the existing crisis of treating antibiotic-resistant bacterial infections. For the innovative aspect of this technology, we have an issued patent on this technology. This technology is patent-protected, and is ready for further development and commercialization. Peptide-based therapeutic and small molecule-based TLR4 modulators are being developed, but SPA4 peptide utilizes a unique and better mechanism and is specifically effective when administered therapeutically in already-infected mice. The unique mechanisms and features of SPA4 peptide are compatible for drug development process. Thus, further development of an SPA4 peptide-based therapeutic will benefit the industry as well as the public health of the society.
Org Type: Academic/Gov Lab
Booth Number: T221